Lexeo Therapeutics (LXEO) Assets (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Assets data on file, last reported at $250.4 million in Q1 2026.

• For the quarter ending Q1 2026, Assets rose 99.19% year-over-year to $250.4 million; the trailing twelve-month figure through Mar 2026 stood at $250.4 million (up 99.19% YoY), and the FY2025 full-year result was $268.7 million, up 82.85% from the prior year.
• Assets slipped to $250.4 million in Q1 2026, from $268.7 million in the prior quarter.
• In the past five years, Assets ranged from a high of $268.7 million in Q4 2025 to a low of $54.7 million in Q3 2023.
• A 5-year average of $165.2 million and a median of $160.4 million in 2024 frame the typical range for Assets.
• Across the five-year window, Assets surged 217.71% in 2024 and plunged 41.05% in 2025, its largest moves.
• Tracing LXEO's Assets over 5 years: stood at $97.1 million in 2022, then jumped by 44.02% to $139.8 million in 2023, then climbed by 5.1% to $146.9 million in 2024, then jumped by 82.85% to $268.7 million in 2025, then declined by 6.82% to $250.4 million in 2026.
• Business Quant data shows LXEO's Assets at $250.4 million in Q1 2026, $268.7 million in Q4 2025, and $143.8 million in Q3 2025.